A132 THREE QUARTERS OF INFLAMMATORY BOWEL DISEASE PATIENTS ON MAINTENANCE INFLIXIMAB THERAPY IN CLINICAL REMISSION SHOW EVIDENCE OF MUCOSAL INFLAMMATION WITH ELEVATED FECAL CALPROTECTIN

摘要

BackgroundFecal calprotectin (FCP) has been demonstrated to be a noninvasive marker of mucosal inflammation and when elevated, correlates with endoscopic mucosal disease activity in patients with Ulcerative Colitis (UC) and Crohn’s Disease (CD). Endoscopic mucosal healing and normalization of FCP represents desired therapeutic results in these patients as it has shown to improve patient outcomes by reducing hospitalization and surgery.